CN107406423B - 强效γ-分泌酶调节剂 - Google Patents

强效γ-分泌酶调节剂 Download PDF

Info

Publication number
CN107406423B
CN107406423B CN201580071837.8A CN201580071837A CN107406423B CN 107406423 B CN107406423 B CN 107406423B CN 201580071837 A CN201580071837 A CN 201580071837A CN 107406423 B CN107406423 B CN 107406423B
Authority
CN
China
Prior art keywords
substituted
unsubstituted
group
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580071837.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107406423A (zh
Inventor
S·L·瓦格纳
W·C·莫布里
R·E·坦齐
G·约翰逊
R·巴克尔
N·梅休
R·J·赫尔
K·D·赖尼尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
University of California, San Diego
Original Assignee
General Hospital Corp
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, University of California, San Diego filed Critical General Hospital Corp
Publication of CN107406423A publication Critical patent/CN107406423A/zh
Application granted granted Critical
Publication of CN107406423B publication Critical patent/CN107406423B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580071837.8A 2014-10-31 2015-10-30 强效γ-分泌酶调节剂 Active CN107406423B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073553P 2014-10-31 2014-10-31
US62/073,553 2014-10-31
PCT/US2015/058429 WO2016070107A1 (en) 2014-10-31 2015-10-30 Potent gamma-secretase modulators

Publications (2)

Publication Number Publication Date
CN107406423A CN107406423A (zh) 2017-11-28
CN107406423B true CN107406423B (zh) 2020-06-16

Family

ID=55858421

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580071837.8A Active CN107406423B (zh) 2014-10-31 2015-10-30 强效γ-分泌酶调节剂

Country Status (8)

Country Link
US (2) US10472346B2 (cg-RX-API-DMAC10.html)
EP (1) EP3212633B1 (cg-RX-API-DMAC10.html)
JP (1) JP6672296B2 (cg-RX-API-DMAC10.html)
CN (1) CN107406423B (cg-RX-API-DMAC10.html)
AU (1) AU2015338946B2 (cg-RX-API-DMAC10.html)
CA (1) CA2966423C (cg-RX-API-DMAC10.html)
MX (1) MX381224B (cg-RX-API-DMAC10.html)
WO (1) WO2016070107A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX381224B (es) 2014-10-31 2025-03-12 Massachusetts Gen Hospital Potentes moduladores de gamma-secretasa.
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
WO2019126731A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
BR112020019373A2 (pt) 2018-03-27 2020-12-29 Ptc Therapeutics, Inc. Compostos para o tratamento da doença de hutington
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
CA3139821A1 (en) * 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CA3169667A1 (en) * 2020-02-28 2021-09-02 Dominic Reynolds Pyridazine derivatives for modulating nucleic acid splicing
WO2023034827A1 (en) * 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
CA2275539A1 (en) 1997-10-28 1999-05-06 Bando Chemical Industries, Ltd. A transdermal patch and a method for manufacture of a substrate sheet therefor
AU2003259965A1 (en) 2002-08-20 2004-03-11 Neurogenetics, Inc. Methods and compositions for modulating amyloid beta
CN102584813B (zh) * 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
PL1828154T3 (pl) 2004-12-09 2009-10-30 Hoffmann La Roche Pochodne fenylopiperazynometanonu
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
KR20090007347A (ko) 2006-03-22 2009-01-16 버텍스 파마슈티칼스 인코포레이티드 증식성 장애의 치료를 위한 ｃ-ＭＥＴ 단백질 키나제 억제제
CA2675755C (en) 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
EP2131654A4 (en) 2007-03-02 2011-02-02 Merck Sharp & Dohme Bipyridine-carboxamide-orexin receptor Antagonist
GB0720444D0 (en) * 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
CA2718727A1 (en) 2008-03-25 2009-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound
RU2515976C2 (ru) 2009-02-26 2014-05-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие конденсированные гетероциклические соединения и их применение в качестве ингибиторов продукции бета-амилоида
JP2012051807A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
JP2012180281A (ja) 2009-06-29 2012-09-20 Dainippon Sumitomo Pharma Co Ltd 新規オキサジアゾール誘導体
WO2011006903A1 (en) 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
JP2013028538A (ja) 2009-11-13 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 新規アミド誘導体
US20130023534A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Pyrazolyl-pyrimidines as kinase inhibitors
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
JP6069661B2 (ja) 2010-06-24 2017-02-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 種々のアミロイドβペプチドアロフォームレベルの調節における組成物及びその使用
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
EP2968296B1 (en) 2013-03-12 2020-09-02 The Regents of the University of California Gamma-secretase modulators
MX381224B (es) 2014-10-31 2025-03-12 Massachusetts Gen Hospital Potentes moduladores de gamma-secretasa.

Also Published As

Publication number Publication date
EP3212633A4 (en) 2018-07-25
US20180093967A1 (en) 2018-04-05
US10472346B2 (en) 2019-11-12
AU2015338946B2 (en) 2020-06-11
EP3212633B1 (en) 2019-12-04
CA2966423C (en) 2023-10-24
US20200055840A1 (en) 2020-02-20
WO2016070107A1 (en) 2016-05-06
CA2966423A1 (en) 2016-05-06
BR112017009010A2 (pt) 2017-12-26
US11117884B2 (en) 2021-09-14
CN107406423A (zh) 2017-11-28
MX2017005715A (es) 2018-02-23
MX381224B (es) 2025-03-12
AU2015338946A1 (en) 2017-06-15
EP3212633A1 (en) 2017-09-06
JP6672296B2 (ja) 2020-03-25
JP2017533237A (ja) 2017-11-09

Similar Documents

Publication Publication Date Title
US11117884B2 (en) Potent gamma-secretase modulators
CN111315737B (zh) 经砜吡啶烷基酰胺取代的杂芳基化合物
CN113227071A (zh) 治疗与IL-12、IL-23和/或IFN-α的调节相关的病症的酰胺取代的杂环化合物
CN103764635B (zh) 新的三氟甲基-噁二唑衍生物及其在疾病治疗中的用途
CN114072393B (zh) 作为mrgx2抑制剂的3-氨基-4h-苯并[e][1,2,4]噻二嗪1,1-二氧化物衍生物
JP7033079B2 (ja) 芳香族スルホンアミド誘導体
TWI635083B (zh) １，４－雙取代嗒類似物及運動神經元存活（ｓｍｎ）缺乏相關病況之治療方式
CN104781252B (zh) 用作IL‑12、IL‑23和/或IFNα应答调节剂的被烷基‑酰胺取代的吡啶化合物
CN111566103B (zh) 作为激酶抑制剂的氨基咪唑并吡嗪
CN113365982A (zh) 酰胺二取代的吡啶或哒嗪化合物
US10023534B2 (en) Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK
TW200403210A (en) Benzamide derivatives
CN104936955A (zh) 噻二唑类似物以及治疗与smn缺乏相关的病症的方法
CN107635992B (zh) 用作tnf抑制剂的三环杂环化合物
TW202028210A (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
TW201326155A (zh) 作為ｇｐｒ１１９調節劑之經哌啶基取代的內醯胺
TWI400238B (zh) ２－酮基烷基－１－哌－２－酮衍生物、其製備及其治療用途
CN102124006B (zh) (桥接的哌嗪基)-1-烷酮衍生物及其作为p75抑制剂的用途
WO2025153625A1 (en) Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
CN111372579A (zh) 取代的苯基磺酰基苯基三唑硫酮和其用途
WO2025153624A1 (en) Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway
JP7025542B2 (ja) Ｔｇｆ－ベータ阻害剤としてのオキサジアゾール及びチアジアゾール
BR122023017838B1 (pt) Uso de moduladores potentes de gama-secretase e método in vitro para reduzir o nível de uma aloforma de peptídeo ab em uma célula
BR112017009010B1 (pt) MODULADORES POTENTES DE GAMA-SECRETASE, SEUS USOS, COMPOSIÇÃO FARMACÊUTICA, MÉTODO PARA REDUZIR O NÍVEL DE UMA ALOFORMA DE PEPTÍDEO Aß EM UMA CÉLULA E PRÓ-FÁRMACO

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant